In epidermal growth factor receptor (EGFR) mutant and anaplastic lymphoma kinase (ALK) rearrangements NSCLC, the ratification and application of EGFR and ALK targeted inhibitors have achieved a pronounced clinical breakthrough, as evidenced by more recently studies for tumors with translocated ROS1 and RET (Drilon et al., 2013). This evidence concerns the gene ALK and non-small cell lung carcinoma.